Loading market data...
Latest Top News
Show more
Cipla Enters Strategic 60:40 Joint Venture With Kemwell To Boost Biologics
Cipla Limited has announced a 60:40 joint venture with Kemwell Biopharma to develop, manufacture, and commercialize biologic products for global markets. Both partners will invest up to INR 10 crores in their respective JV ratio, marking a significant step in Cipla’s biologics expansion strategy.
Stay Ahead – Explore Now! Paycheque to peace: The 80% retirement rule, demystified






